Comparative Pharmacology
Head-to-head clinical analysis: TESTOPEL versus TLANDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOPEL versus TLANDO.
TESTOPEL vs TLANDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone is an androgen receptor agonist; it binds to and activates androgen receptors, leading to changes in gene expression that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects.
TLANDO (testosterone undecanoate) is an androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle mass, bone density, and secondary sexual characteristics. Testosterone is converted to dihydrotestosterone (DHT) via 5α-reductase in target tissues, exerting both androgenic and anabolic effects.
Subcutaneous implantation: 150-450 mg every 3-6 months. Individualize based on serum testosterone levels and clinical response.
TLANDO (testosterone undecanoate) is administered orally. The recommended adult dose is 225 mg twice daily (approximately every 12 hours) with a meal containing fat. Swallow capsules whole; do not chew or crush.
None Documented
None Documented
Terminal half-life: 8-10 days; due to prolonged release from subcutaneous depot, effective half-life extends to 2-3 weeks.
The terminal elimination half-life of testosterone is 10-100 minutes; however, for TLANDO (testosterone undecanoate) after oral administration, the apparent half-life is approximately 7-10 hours due to the slow release from chylomicrons and prolonged absorption.
Renal: ~90% as glucuronide and sulfate conjugates, ~10% unchanged; fecal: ~6% via biliary elimination.
Approximately 90% of a dose is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites; about 6% is excreted in feces via bile. Unchanged testosterone accounts for less than 1% of urinary excretion.
Category C
Category C
Androgen
Androgen/hormone replacement